Target Company Information

Dymon Asia Private Equity has successfully positioned itself in the medical waste disposal sector through its acquisition of Asia Medical Enviro Services (AMES), a leading provider of medical and biohazardous waste management in Singapore. Dymon purchased AMES for S$20 million ($15 million) from Sembcorp in 2020, with a strategy to leverage its established market presence and expand revenues significantly amid increasing demand due to the COVID-19 pandemic.

Prior to the pandemic, AMES was already recognized as a local leader in this sector, commanding approximately 75% of the market share, including over 70% of government-run hospitals. The organization's response to the pandemic has been transformational, capitalizing on the surge in medical waste produced in various healthcare settings.

Industry Overview in Singapore

The medical waste disposal industry in Singapore has experienced a marked increase in importance, especially in light of recent global health crises. The National Environment Agency reported a steady rise in medical waste of about 5% annually from 2016 to 2020, with an average production of 16 metric tons per day in pre-pandemic conditions. However, this figure skyrocketed post-pandemic, reaching approximately 186 metric tons daily, as per research by the University of Phayao.

This surge is further compounded by rising safety and environmental compliance standards, which include broad access to personal protective equipment (PPE). The increased healthcare demands from the pandemic have not been confined to Singapore; cities across Southeast Asia, such as Manila, Jakarta, and Kuala Lumpur, have similarly seen their daily waste tonnages grow significantly, though Singapore's increase remains unparalleled within the region.

As the medical waste management sector adapts to these heightened requirements, competition has intensified. AMES, facing about six notable competitors, has needed to remain agile in fulfilling the growing demand while ensuring regulatory compliance and environmental safety measures are upheld adequately.

Rationale Behind the Deal

The rationale for Dymon’s investment in AMES rests on the anticipated growth of the medical waste disposal market driven by COVID-19. With a well-established market position and the added urgency for effective waste disposal solutions due to the pandemic, Dymon saw an opportunity to drive AMES’ revenue and EBITDA substantially—both of which increased by approximately 40% per year since the acquisition.

Furthermore, Dymon's experience in the healthcare sector, underscored by its successful exit from UEMS, positioned it to navigate AMES through a volatile but profitable market landscape effectively. The firm’s proactive measures, such as acquiring protective equipment prior to local outbreaks, reflect its strategic foresight in capitalizing on emerging trends within the sector.

Investor Information

Dymon Asia Private Equity is a seasoned investment firm with a focus on the Asia-Pacific region. They manage a commitment of $450 million through their second fund which closed in 2020, indicating substantial confidence and liquidity for future investments. Dymon’s deep understanding of the healthcare industry, coupled with its successful track record in transforming operations and generating returns, makes it a formidable player in the private equity sphere.

The firm emphasizes creating value in its portfolio companies while adhering to high operational standards. Dymon’s ability to navigate complex investment landscapes and align with local market dynamics has been instrumental in its success with AMES.

View of Dealert

Dealert’s analysis indicates that Dymon’s acquisition of AMES could indeed be a strong investment given the prevailing conditions in the medical waste sector. The dramatic rise in demand prompted by the COVID-19 pandemic not only validates Dymon’s acquisition strategy but also positions AMES for long-term sustainability and growth within the market.

Furthermore, the company's solid market share and the ongoing needs of the healthcare sector ensure a recurring revenue stream, which is critical in attaining robust returns on investment. With AMES’ revenue and EBITDA projected to continue doubling their pre-pandemic levels, the landscape suggests that Dymon has made a calculated investment that is likely to yield positive results in the coming years.

In conclusion, while external market pressures exist, such as competition and regulatory scrutiny, the consistent demand for medical waste disposal indicates a resilient sector. Thus, the deal represents an opportunistic move into a vital service area, which aligns with increasing public health priorities.

View Original Article